Nebivolol

證據等級: L5

預測適應症: 10 個

Nebivolol: From Hypertension to Malignant Renovascular Hypertension

One-Sentence Summary

Nebivolol is a third-generation, β1-selective adrenergic blocker with nitric-oxide-mediated vasodilatory action, originally used to treat hypertension. The TxGNN model’s top-ranked prediction for this drug is malignant renovascular hypertension, but currently no clinical trials or published literature directly support this specific indication.

Quick Overview

Item	Content
Original Indication	Hypertension (per drug-class literature in this evidence pack)
Predicted New Indication	Malignant Renovascular Hypertension
TxGNN Prediction Score	99.42%
Evidence Level	L5
Australia Market Status	Not marketed
Number of ARTG Entries	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data for Nebivolol is not available in this evidence pack (flagged as a High-severity data gap). Based on known information within the supporting literature (e.g. PMID 19393838, 31066991, 30426333), Nebivolol is a third-generation β1-selective adrenoceptor antagonist that also promotes nitric-oxide-mediated vasodilation, and its efficacy in essential hypertension is well established.

Malignant renovascular hypertension is a severe, renin-angiotensin-driven subtype of hypertension, so there is a plausible pharmacological class-level link to a general antihypertensive agent. However, this is a theoretical extension rather than a demonstrated one: malignant hypertension is a hypertensive emergency typically managed with intravenous antihypertensives for rapid blood pressure control, and oral β-blockers such as nebivolol are not standard first-line therapy in this acute setting. No trial or publication in this evidence pack tests nebivolol specifically in this population.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available.

Safety Considerations

Please refer to the TGA-approved Product Information (PI) for safety information.

Conclusion and Next Steps

Decision: Hold

Rationale: Despite a high TxGNN prediction score, there is zero clinical trial or literature evidence for nebivolol in malignant renovascular hypertension, and the acute/emergency nature of this condition makes an oral β-blocker mechanistically questionable as monotherapy. Evidence is insufficient to progress beyond hypothesis stage.

To proceed, the following is needed:

Direct pharmacological or clinical evidence linking nebivolol specifically to renovascular/malignant hypertension
TFDA/TGA Product Information (PI) — labelled warnings and contraindications are currently a blocking data gap (DG001)
Confirmed mechanism of action from DrugBank (DG002)
Confirmation of Australian regulatory/ARTG status, as the drug is currently not marketed

Note: Other Predicted Indications with Stronger Evidence

The same evidence pack contains two lower-ranked predictions with meaningfully more support than the top-ranked candidate above, worth flagging for anyone triaging this drug’s repurposing portfolio:

Rank	Indication	Evidence Level	Decision Stage	Key Support
6	Chronic pulmonary heart disease (cor pulmonale)	L2	Research Question	4 clinical trials incl. a head-to-head Phase 4 vs. carvedilol/bisoprolol in heart failure and hypoxia (NCT00517725, NCT00924833); 18 literature entries on β-blocker safety in COPD/HF overlap
7	Prinzmetal (vasospastic) angina	L2	Research Question	Direct Phase 4 completed trial “The Effect of Nebivolol in Hypertensive Patients With Coronary Arterial Spasm” (NCT03930433, n=51)

By contrast, ranks 1–5, 8–10 (including the title indication above) are all Evidence Level L5 with no supporting trials or literature — several (e.g. Braddock syndrome, ocular tuberculosis, congenital TMJ ankylosis) appear to be knowledge-graph noise with no plausible mechanistic link.

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.